Gregory R. Friberg, M.D.

Gregory R. Friberg, M.D.

Executive Vice President, Chief Research & Development OfficeratBiomarin Pharmaceutical· In proxies 2024–2025

Pay in FY2025-1% from the year before · Biomarin Pharmaceutical stock -9.6% the same year

Gregory R. Friberg, M.D. was paid $7.2M in FY2025 (Dec), down 1%. Biomarin Pharmaceutical stock fell 9.6% that year.

Pay$100 in the stock at the end of FY23 → $62
Pay is from the Summary Compensation Table of each Biomarin Pharmaceutical proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Biomarin PharmaceuticalPublic company · 2 yr
    • Executive Vice President, Chief Research & Development Officer2024 – Present · 2 yrStock in role -42%

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?